Alive's first portfolio exit: Innovalve, a transcatheter mitral valve replacement developer, was acquired by Edwards Lifesciences for approximately $350M.
Innovalve develops catheter-based heart valve technology, designed to treat cardiovascular diseases
Innovalve develops catheter-based heart valve technology, designed to treat cardiovascular diseases. The company's platform offers an artificial mitral valve that can be replaced, using a minimally-invasive catheter and act as a substitute in heart surgery, enabling healthcare professionals to get an alternate way to treat patients suffering from cardiovascular diseases.